New combo therapy aims to shrink rectal tumors before surgery
NCT ID NCT07509424
Summary
This study is testing a new combination of treatments for people with locally advanced rectal cancer that has a specific protein marker (HER2). The goal is to shrink the tumor before surgery to make it easier to remove. Participants will receive a short course of radiation, followed by several cycles of three different drugs. Doctors will then check if the tumor has shrunk enough for surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.